ANKASCIN® 568-R – When science meets both market trend and government policies

Ankascin 568-R ingredient image1-20230331


“The superior effects of MS and AK in ANKASCIN® 568-R show significant results, from managing glycation and inflammation to improving hyperglycemia, hyperlipidemia, hypertension, and cognitive health. This novel ingredient is clinically proven, safe, has multiple applications in dietary supplements and functional food, is compliant with EU and US regulations, and provides excellent support for healthy aging.”


According to the WHO, around one in ten people in Europe or US has diabetes, which means that if you go out with your relatives, there’s a good chance that the person you’re arm-in-arm with is someone who has diabetes. Chronic diabetic complications, including hyperlipidemia, hypertension, or Alzheimer’s disease, have been related to advanced glycation end product (AGE) accumulation. Glycation and AGEs lead to accelerated organ aging, thus causing the vicious cycle of tissue glycation and aging. However, the Western diet, which is full of AGEs, and COVID-19 have aggravated this already grim scenario. Reports show that patients with hyperglycemia and COVID-19 have a 2-to-4-fold risk of severe COVID-19 or death than those without diabetes.

ANKASCIN® 568-R is a state-of-the-art ingredient containing high MS and AK levels. It addresses the root cause, mainly via PPARγ/Nrf2 pathways, to manage anti-glycation, antioxidant, and anti-inflammation and acts synergistically in improving the impairment of pancreatic β-cell function (blood glucose regulation), resolving lipid plaque accumulation in the blood vessels (blood lipids regulation), and improving vascular elastin structure remodeling (blood pressure regulation).

ANKASCIN® 568-R also alleviates Alzheimer’s disease through the blood glucose regulation pathway (PPARγ/Nrf2 pathway) by alleviating neuroinflammation, APP, Aβ, and pTau accumulation, improving cognitive function, and reversing behavioral deficits.


How do we break through the limitation of government policy and make it even better?

Individuals who use supplements containing active ingredients in conjunction with prescription drugs may experience unexpected side effects. Monacolin K (MK) is a naturally occurring active compound in red yeast rice that is structurally identical to prescription drugs (lovastatin/statins). The US FDA has classified red yeast rice (RYR) products containing more than a trace amount of MK as unapproved new drugs since 1998, meaning RYR containing MK cannot be sold legally as a dietary supplement in the US. Moreover, new EU regulations from 2022 have restricted the content of MK (3 mg/daily dosage) of red yeast rice products.

SunWay’s SQP system has patented the fermentation and extraction process to control humidity and temperature to guarantee that our product fits in the strictest citrinin level policy (no more than 100 ppb) and contains zero MK! To reach net-zero emissions, SunWay’s SQP system is 75% reduction in energy demand and produces zero wastewater compared to the traditional liquid-state fermentation method.

The aim of the SQP system is to produce two research-proven active compounds: MS and AK. In maximizing the potential benefits for hyperglycemia, hyperlipidemia, and hypertension management and improving Alzheimer’s disease, it is superior to traditional RYR management. Another benefit is elevating the application level. The effective dosage of ANKASCIN® 568-R is only 110-220 mg compared to traditional RYR, which requires 1200-2400 mg daily.

ANKASCIN® 568-R has passed multiple safety assessments proving no effects on risk factors like creatine phosphokinase, AST, and ALT levels and no drug interactions when combined with drugs treating hyperlipidemia, hyperglycemia, or hypertension. ANKASCIN® 568-R is also required as the New Dietary Ingredient (NDI) by the US FDA, which means it is the only eligible RYR ingredient on the US market that could legally apply claims and clearly specify the contents of active compounds.


Product development for dietary supplements and functional food

ANKASCIN® 568-R can be formulated into capsules, tablets, soft gels, powder-packed products, and oatmeal and chocolate due to its small effective dosage. Therefore, it is suitable to meet dynamic consumer needs and regulatory requirements.


Marketing recognition

This year, we are thrilled to announce that ANKASCIN® 568-R has been recognized as a finalist for the Healthy Aging Ingredient of the Year at the Nutraingredients Awards 2023! Nutraingredients Awards Ingredient of the Year awards aim to celebrate the best ingredients and innovations that the industry has to offer in key consumer categories. Therefore, ANKASCIN® 568-R is now shining and recognized among international dietary supplement judges.


Official recognition

  1. US FDA-approved New Dietary Ingredient
  2. Red yeast standard in US Pharmacopeia (USP) PF48(6) Monographs.
  3. HALAL certification


For more information, please contact us



Disclaimer: This communication is only intended for business-to-business. Nothing on this page is meant to be perceived as an approved claim by regulatory authorities.